You are here: Industry Insights > AbbVie

News List

AbbVie's first-quarter sales top estimates, boosted by Humira, hepatitis C drugs firstwordpharma
April 27, 2018
AbbVie announced Thursday that first-quarter sales increased 21.4 percent year-over-year to $7.9 billion, topping analyst estimates of $7.6 billion
Strong Sales of Humira, Imbruvica and HCV Drug Mavyret Drive AbbVie’s Strong First Quarter biospace
April 27, 2018
Humira, the world’s best-selling drug, keeps on churning out positive sales results for AbbVie, despite looming challenges.
AbbVie seeks US approval of risankizumab for plaque psoriasis; reports positive data for upadacitinib in rheumatoid arthritis firstwordpharma
April 26, 2018
AbbVie announced Wednesday the submission of an application to the FDA seeking approval of risankizumab for the treatment of patients with moderate-to-severe plaque psoriasis
US delay for AbbVie/Neurocrine’s uterine pain drug pharmatimes
April 13, 2018
The US Food and Drug Administration has extended its review of AbbVie and Neurocrine’s experimental uterine pain drug elagolix by three months.
FDA Pushes Back PDUFA Date for AbbVie’s Endometriosis Drug biospace
April 12, 2018
The U.S. Food and Drug Administration wants more time to review AbbVie’s elagolix, a treatment for endometriosis-associated pain.
Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis biospace
April 10, 2018
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-COMPARE clinical trial
AbbVie’s Arthritis Drug Dazzles in Phase III Trial biospace
April 10, 2018
AbbVie announced positive top-line data from its Phase III SELECT-COMPARE clinical trial of upadacitinib in moderate to severe rheumatoid arthritis.
AbbVie Strikes Deal: Blockbuster Humira is Safe Until 2023 biospace
April 08, 2018
U.S. sales of AbbVie’s blockbuster Humira is safe from a biosimilar challenge from Samsung Bioepis, a joint project between Samsung and Biogen, until 2023.
Abbvie pays out over $3m after its testosterone replacement drug leads to heart attack pharmafile
March 28, 2018
Abbvie has been ordered to pay over $3 million in damages to a man who asserts that the uise of the company’s testosterone replacement drug AndroGel drove him to a heart attack, a risk which he argues was vastly misrepresented.
After Rova-T Failure, A Look at AbbVie’s Pipeline biospace
March 28, 2018
AbbVie announced that after the disappointment of Phase II clinical trials, it will not require the FDA to accelerate the approval of Rova-T for use in three-line recurrence/refractory (R/R) small cell lung cancer

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page